Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: A literature review
Imatinib mesylate is a drug that has been approved for treatment of advanced gastrointestinal stromal tumors (GISTs) and patients with leukemia such as chronic myeloid or Philadelphia chromosome-positive acute lymphoblastic. Although it has been described only in one patient with testicular hydrocel...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice 2012-06, Vol.18 (2), p.303-310 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 310 |
|---|---|
| container_issue | 2 |
| container_start_page | 303 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 18 |
| creator | Tanriverdi, Ozgur Unubol, Mustafa Taskin, Fisun Meydan, Nezih Sargin, Gokhan Guney, Engin Barutca, Sabri |
| description | Imatinib mesylate is a drug that has been approved for treatment of advanced gastrointestinal stromal tumors (GISTs) and patients with leukemia such as chronic myeloid or Philadelphia chromosome-positive acute lymphoblastic. Although it has been described only in one patient with testicular hydrocele and gynecomastia in the literature, several cases of male gynecomastia have been reported with the use of imatinib mesylate in chronic myeloid leukemia (GML). Generally, male mastoplasia resolves after discontinuation of imatinib treatment. We report a 73-year-old male with metastatic GISTs who developed gynecomastia and unilateral testicular hydrocele while receiving imatinib mesylate. Nine months after commencing imatinib treatment, gynecomastia and testicular hydrocele were determined. Hormone analyses requested showed serum testosterone levels below and serum estrogen levels above normal limits. During the first month after discontinuing imatinib mesylate treatment, serum testosterone level was normal and there was a partial regression in gynecomastia and testicular hydrocele. To our knowledge, this is the second report of male gynecomastia following imatinib mesylate treatment of a patient with GIST. In conclusion, male patients who are to receive treatment with imatinib mesylate may be monitored for serum testosterone levels and for other reproductive hormone profiles before initiation of the treatment and their breasts may be examined during follow-up visits. |
| doi_str_mv | 10.1177/1078155211424629 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1012749247</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155211424629</sage_id><sourcerecordid>1012749247</sourcerecordid><originalsourceid>FETCH-LOGICAL-c280t-b260b1cf195758def9daeedbf06ef2522fefcc879c7d55ecc82df1af76c5ddd93</originalsourceid><addsrcrecordid>eNp1kUFLHTEQgENpqdb27kkCvXjZNom7LxtvItUKQi8t9LZkk8kzskmeSbby_o6_1FmflSL0NJOZb74kDCGHnH3hXMqvnMmed53gvBXtSqg3ZJ-3UjZMid9vMcd2s_T3yIdSbhljvRT9e7InBGNKMr5PHq6Crj76sdGlJON1BUtHP2HMeqLrbQSTgi7Va6qjpXN86VXAqpknnenN1uZkYALqIw0a4watECu99_WGBqhowIqha0xy8vFpOKJlOYbFNoeUT-kZnfyir3MGmuGPh_uP5J3TU4FPz_GA_Lr49vP8e3P94_Lq_Oy6MaJntRnFio3cOK462fUWnLIawI6OrcCJTggHzpheKiNt1wGmwjqunVyZzlqrTg7I8c67yeluxvcNwRf81KQjpLkMnHEhWyVaiejnV-htmjN-Z0cx1YuTFim2o0xOpWRwwyb7oPMWoWHZ3_B6fzhy9CyexwD2ZeDvwhBodkDRa_j31v8IHwGQeKhD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1012098234</pqid></control><display><type>article</type><title>Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: A literature review</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Tanriverdi, Ozgur ; Unubol, Mustafa ; Taskin, Fisun ; Meydan, Nezih ; Sargin, Gokhan ; Guney, Engin ; Barutca, Sabri</creator><creatorcontrib>Tanriverdi, Ozgur ; Unubol, Mustafa ; Taskin, Fisun ; Meydan, Nezih ; Sargin, Gokhan ; Guney, Engin ; Barutca, Sabri</creatorcontrib><description>Imatinib mesylate is a drug that has been approved for treatment of advanced gastrointestinal stromal tumors (GISTs) and patients with leukemia such as chronic myeloid or Philadelphia chromosome-positive acute lymphoblastic. Although it has been described only in one patient with testicular hydrocele and gynecomastia in the literature, several cases of male gynecomastia have been reported with the use of imatinib mesylate in chronic myeloid leukemia (GML). Generally, male mastoplasia resolves after discontinuation of imatinib treatment. We report a 73-year-old male with metastatic GISTs who developed gynecomastia and unilateral testicular hydrocele while receiving imatinib mesylate. Nine months after commencing imatinib treatment, gynecomastia and testicular hydrocele were determined. Hormone analyses requested showed serum testosterone levels below and serum estrogen levels above normal limits. During the first month after discontinuing imatinib mesylate treatment, serum testosterone level was normal and there was a partial regression in gynecomastia and testicular hydrocele. To our knowledge, this is the second report of male gynecomastia following imatinib mesylate treatment of a patient with GIST. In conclusion, male patients who are to receive treatment with imatinib mesylate may be monitored for serum testosterone levels and for other reproductive hormone profiles before initiation of the treatment and their breasts may be examined during follow-up visits.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155211424629</identifier><identifier>PMID: 22009701</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Aged ; Antineoplastic Agents - adverse effects ; Benzamides ; Chemotherapy ; Gastrointestinal Neoplasms - drug therapy ; Gastrointestinal Stromal Tumors - drug therapy ; Gynecomastia - chemically induced ; Gynecomastia - diagnosis ; Humans ; Imatinib Mesylate ; Leukemia ; Male ; Mens health ; Pharmacology ; Piperazines - adverse effects ; Pyrimidines - adverse effects ; Reproductive system ; Testicular Hydrocele - chemically induced ; Testicular Hydrocele - diagnosis ; Tumors</subject><ispartof>Journal of oncology pharmacy practice, 2012-06, Vol.18 (2), p.303-310</ispartof><rights>The Author(s) 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</rights><rights>SAGE Publications © Jun 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c280t-b260b1cf195758def9daeedbf06ef2522fefcc879c7d55ecc82df1af76c5ddd93</citedby><cites>FETCH-LOGICAL-c280t-b260b1cf195758def9daeedbf06ef2522fefcc879c7d55ecc82df1af76c5ddd93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1078155211424629$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1078155211424629$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22009701$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanriverdi, Ozgur</creatorcontrib><creatorcontrib>Unubol, Mustafa</creatorcontrib><creatorcontrib>Taskin, Fisun</creatorcontrib><creatorcontrib>Meydan, Nezih</creatorcontrib><creatorcontrib>Sargin, Gokhan</creatorcontrib><creatorcontrib>Guney, Engin</creatorcontrib><creatorcontrib>Barutca, Sabri</creatorcontrib><title>Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: A literature review</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Imatinib mesylate is a drug that has been approved for treatment of advanced gastrointestinal stromal tumors (GISTs) and patients with leukemia such as chronic myeloid or Philadelphia chromosome-positive acute lymphoblastic. Although it has been described only in one patient with testicular hydrocele and gynecomastia in the literature, several cases of male gynecomastia have been reported with the use of imatinib mesylate in chronic myeloid leukemia (GML). Generally, male mastoplasia resolves after discontinuation of imatinib treatment. We report a 73-year-old male with metastatic GISTs who developed gynecomastia and unilateral testicular hydrocele while receiving imatinib mesylate. Nine months after commencing imatinib treatment, gynecomastia and testicular hydrocele were determined. Hormone analyses requested showed serum testosterone levels below and serum estrogen levels above normal limits. During the first month after discontinuing imatinib mesylate treatment, serum testosterone level was normal and there was a partial regression in gynecomastia and testicular hydrocele. To our knowledge, this is the second report of male gynecomastia following imatinib mesylate treatment of a patient with GIST. In conclusion, male patients who are to receive treatment with imatinib mesylate may be monitored for serum testosterone levels and for other reproductive hormone profiles before initiation of the treatment and their breasts may be examined during follow-up visits.</description><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Benzamides</subject><subject>Chemotherapy</subject><subject>Gastrointestinal Neoplasms - drug therapy</subject><subject>Gastrointestinal Stromal Tumors - drug therapy</subject><subject>Gynecomastia - chemically induced</subject><subject>Gynecomastia - diagnosis</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia</subject><subject>Male</subject><subject>Mens health</subject><subject>Pharmacology</subject><subject>Piperazines - adverse effects</subject><subject>Pyrimidines - adverse effects</subject><subject>Reproductive system</subject><subject>Testicular Hydrocele - chemically induced</subject><subject>Testicular Hydrocele - diagnosis</subject><subject>Tumors</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kUFLHTEQgENpqdb27kkCvXjZNom7LxtvItUKQi8t9LZkk8kzskmeSbby_o6_1FmflSL0NJOZb74kDCGHnH3hXMqvnMmed53gvBXtSqg3ZJ-3UjZMid9vMcd2s_T3yIdSbhljvRT9e7InBGNKMr5PHq6Crj76sdGlJON1BUtHP2HMeqLrbQSTgi7Va6qjpXN86VXAqpknnenN1uZkYALqIw0a4watECu99_WGBqhowIqha0xy8vFpOKJlOYbFNoeUT-kZnfyir3MGmuGPh_uP5J3TU4FPz_GA_Lr49vP8e3P94_Lq_Oy6MaJntRnFio3cOK462fUWnLIawI6OrcCJTggHzpheKiNt1wGmwjqunVyZzlqrTg7I8c67yeluxvcNwRf81KQjpLkMnHEhWyVaiejnV-htmjN-Z0cx1YuTFim2o0xOpWRwwyb7oPMWoWHZ3_B6fzhy9CyexwD2ZeDvwhBodkDRa_j31v8IHwGQeKhD</recordid><startdate>201206</startdate><enddate>201206</enddate><creator>Tanriverdi, Ozgur</creator><creator>Unubol, Mustafa</creator><creator>Taskin, Fisun</creator><creator>Meydan, Nezih</creator><creator>Sargin, Gokhan</creator><creator>Guney, Engin</creator><creator>Barutca, Sabri</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201206</creationdate><title>Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: A literature review</title><author>Tanriverdi, Ozgur ; Unubol, Mustafa ; Taskin, Fisun ; Meydan, Nezih ; Sargin, Gokhan ; Guney, Engin ; Barutca, Sabri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c280t-b260b1cf195758def9daeedbf06ef2522fefcc879c7d55ecc82df1af76c5ddd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Benzamides</topic><topic>Chemotherapy</topic><topic>Gastrointestinal Neoplasms - drug therapy</topic><topic>Gastrointestinal Stromal Tumors - drug therapy</topic><topic>Gynecomastia - chemically induced</topic><topic>Gynecomastia - diagnosis</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia</topic><topic>Male</topic><topic>Mens health</topic><topic>Pharmacology</topic><topic>Piperazines - adverse effects</topic><topic>Pyrimidines - adverse effects</topic><topic>Reproductive system</topic><topic>Testicular Hydrocele - chemically induced</topic><topic>Testicular Hydrocele - diagnosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanriverdi, Ozgur</creatorcontrib><creatorcontrib>Unubol, Mustafa</creatorcontrib><creatorcontrib>Taskin, Fisun</creatorcontrib><creatorcontrib>Meydan, Nezih</creatorcontrib><creatorcontrib>Sargin, Gokhan</creatorcontrib><creatorcontrib>Guney, Engin</creatorcontrib><creatorcontrib>Barutca, Sabri</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanriverdi, Ozgur</au><au>Unubol, Mustafa</au><au>Taskin, Fisun</au><au>Meydan, Nezih</au><au>Sargin, Gokhan</au><au>Guney, Engin</au><au>Barutca, Sabri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: A literature review</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2012-06</date><risdate>2012</risdate><volume>18</volume><issue>2</issue><spage>303</spage><epage>310</epage><pages>303-310</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Imatinib mesylate is a drug that has been approved for treatment of advanced gastrointestinal stromal tumors (GISTs) and patients with leukemia such as chronic myeloid or Philadelphia chromosome-positive acute lymphoblastic. Although it has been described only in one patient with testicular hydrocele and gynecomastia in the literature, several cases of male gynecomastia have been reported with the use of imatinib mesylate in chronic myeloid leukemia (GML). Generally, male mastoplasia resolves after discontinuation of imatinib treatment. We report a 73-year-old male with metastatic GISTs who developed gynecomastia and unilateral testicular hydrocele while receiving imatinib mesylate. Nine months after commencing imatinib treatment, gynecomastia and testicular hydrocele were determined. Hormone analyses requested showed serum testosterone levels below and serum estrogen levels above normal limits. During the first month after discontinuing imatinib mesylate treatment, serum testosterone level was normal and there was a partial regression in gynecomastia and testicular hydrocele. To our knowledge, this is the second report of male gynecomastia following imatinib mesylate treatment of a patient with GIST. In conclusion, male patients who are to receive treatment with imatinib mesylate may be monitored for serum testosterone levels and for other reproductive hormone profiles before initiation of the treatment and their breasts may be examined during follow-up visits.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>22009701</pmid><doi>10.1177/1078155211424629</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2012-06, Vol.18 (2), p.303-310 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1012749247 |
| source | Access via SAGE; MEDLINE |
| subjects | Aged Antineoplastic Agents - adverse effects Benzamides Chemotherapy Gastrointestinal Neoplasms - drug therapy Gastrointestinal Stromal Tumors - drug therapy Gynecomastia - chemically induced Gynecomastia - diagnosis Humans Imatinib Mesylate Leukemia Male Mens health Pharmacology Piperazines - adverse effects Pyrimidines - adverse effects Reproductive system Testicular Hydrocele - chemically induced Testicular Hydrocele - diagnosis Tumors |
| title | Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: A literature review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T11%3A17%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imatinib-associated%20bilateral%20gynecomastia%20and%20unilateral%20testicular%20hydrocele%20in%20male%20patient%20with%20metastatic%20gastrointestinal%20stromal%20tumor:%20A%20literature%20review&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Tanriverdi,%20Ozgur&rft.date=2012-06&rft.volume=18&rft.issue=2&rft.spage=303&rft.epage=310&rft.pages=303-310&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155211424629&rft_dat=%3Cproquest_cross%3E1012749247%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1012098234&rft_id=info:pmid/22009701&rft_sage_id=10.1177_1078155211424629&rfr_iscdi=true |